Nonenzymatic glycation of α-synuclein and changes in its conformation

Progress in Biochemistry and Biophysics

Volumn 35, Issue 10, 2008, Pages 1202-1208

  Zhi Ling, Sheng ^a,b,c   Yan Ying, L I U ^a   Lan, Chen ^a   Rong Qiao, H E ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c ZHENGZHOU UNIVERSITY   (China)

Author keywords

synuclein; Characteristic fluorescence; Molecular aggregation; Molecular conformation; Neurodegeneration; Nonenzymatic glycation

Indexed keywords

EID: 59749095482     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Spillantini M G, Schmidt M L, Lee V M, et al. Alpha-synuclein in Lewy bodies. Nature, 1997, 388(6645): 839-840
2. Trojanowski J Q, Lee V M. Aggregation of neurofilament and alphasynuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol, 1998, 55(2): 151-152
3. Trojanowski J Q, Lee V M. Parkinson's disease and related neurodegenerative synucleinopathies linked to progressive accumulations of synuclein aggregates in brain. Parkinsonism Relat Disord, 2001, 7(3): 247-251
4. Kosaka K. Diffuse neurofibrillary tangles with calcifications: a new presenile dementia. J Neurol Neurosurg Psychiatry, 1994, 57(5): 594-596
5. Lavedan C. The synuclein family. Genome Res, 1998, 8(9): 871-880
6. Polymeropoulos M H, Lavedan C, Leroy E, et al. Mutation in the alphasynuclein gene identified in families with Parkinson's disease. Science, 1997, 276(5321): 2045-2047
7. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet, 1998, 18(2): 106-108
8. Tofaris G K, Spillantini M G. Physiological and pathological properties of alpha-synuclein. Cell Mol Life Sci, 2007, 64(17): 2194-2201
9. Dawson T M, Dawson V L. Molecular pathways of neurodegeneration in Parkinson's disease. Science, 2003, 302(5646): 819-822
10. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron, 2003, 39(6): 889-909
11. Conway K A, Harper J D, Jr Lansbury P T. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry (Mosc), 2000, 39(10): 2552-2563
12. Beger K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol, 2006, 112(3): 237-251
13. Munch G, Luth H J, Wong A, et al. Crosslinking of α-synuclein by advanced glycation endproductsan early pathophysiological step in Lewy body formation?. J Chem Neuroanat, 2000, 20(3-4): 253-257
14. Huang C H, Ren G P, Zhou H, et al. A new method for purification of recombinant human α-synuclein in Escherichia coli. Protein Expr Purif, 2005, 42(1): 173-177
15. Jenco J M, Rawlingson A, Daniels B, et al. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry (Mosc), 1998, 37(14): 4901-4909
16. Maroteaux L, Scheller R H. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res, 1991, 11(3-4): 335-343
17. Papachroni K, Ninkina N, Wanless J, et al. Peripheral sensory neurons survive in the absence of alpha and gamma-synucleins. J Mol Neurosci, 2005, 25(2): 157-164
18. Sidhu A, Wersinger C, Moussa C E, et al. The role of alpha-synuclein in both neuroprotection and neurodegeneration. Ann N Y Acad Sci, 2004, 1035(1): 250-270
19. Chinese source
20. Chinese source
21. Munch G, Schicktanz D, Behme A, et al. Amino acid specificity of glycation and protein-AGE crosslinking reactivities determined with a dipeptide SPOT library. Nat Biotechnol, 1999, 17(10): 1006-1010
22. LÜth H J, Ogunlade V, Kuhla B, et al. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. Cereb Cortex, 2005, 15(2): 211-220
23. Reddy V P, Obrenovich M, Atwood C S, et al. Involvement of Maillard reactions in Alzheimer disease. Neurotox Res, 2002, 4(3): 191-209
24. Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol, 1992, 23: 1-34
25. Singh R, Barden A, Mori T, et al. Advanced glycation endproducts: a review. Diabetologia, 2001, 44: 129-146
26. Vlassara H, Uribarri J. Glycoxidation and diabetic complications: modern lessons and a warning?. Rev Endocr Metab Disord, 2004, 5 (3): 181-188
27. Schmidt A M, Yan S D, Wautier J L, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res, 1999, 84(5): 489-497
28. Artwohl M, Graier W, Roden M, et al. Diabetic LDL triggers apoptosis in vascular endothelial cells. Diabetes, 2003, 52 (5): 1240-1247
29. Kaji Y, Amano S, Usui T, et al. Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. Invest Ophthalmol Vis Sci, 2003, 44(2): 521-528
30. Schalkwijk C G, Stehouwer C D A, van Victor W M, et al. Fructose- mediated non-enzymatic glycation: sweet coupling or bad modification. Diabetes Metab Res Rev, 2004, 20(5): 369-382